test

Nikolai Alexandrovich Podoltsev MD, PhD

Assistant Professor of Medicine (Hematology); Associate Director of the Hematology/Oncology Fellowship Program

Clinical Interests

myeloprolipherative neoplasms (MPN); myelodysplastic syndromes (MDS); acute leukemias


Board Certifications

2010
Hematology (Internal Medicine), Board Certified
2010
Medical Oncology, Board Certified
2000
Internal Medicine, Board Certified

Patient Care Locations

nikolai_podoltsevfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Antiphospholipid Syndrome (APS)Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Myeloid and Monocytic LeukemiaE2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, otherA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Lymphoid LeukemiaE1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Leukemia, not otherwise specified, Leukemia, other, and Myeloid and Monocytic LeukemiaA Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease

More Clinical Trials...

Edit Profile